BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants

Cancer Research

Volumn 66, Issue 1, 2006, Pages 41-45

  Elstrodt, Fons ^a   Hollestelle, Antoinette ^a   Nagel, Jord H A ^a   Gorin, Michael ^b   Wasielewski, Marijke ^a   Van Den Ouweland, Ans ^a   Merajver, Sofia D ^b   Ethier, Stephen P ^c   Schutte, Mieke ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE DERIVATIVE; BRCA1 PROTEIN; GUANINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AB1; MONOCLONAL ANTIBODY AB2; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA REPAIR; EXON; GENE DELETION; GENE SEQUENCE; GERM LINE; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; SEQUENCE ANALYSIS;

ADENOCARCINOMA; ADULT; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENES, BRCA1; HUMANS; MUTATION;

EID: 31544474577     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2853     Document Type: Article

References (14)

1. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000;408:429-32.
2. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82.
3. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002;8:571-6.
4. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol 2003;15:345-50.
5. Tomlinson GE, Chen TT, Stastny VA, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 1998;58:3237-42.
6. Hartes IC, Elstrodt F, Dinjens WN, et al. Allelotype of 28 human breast cancer cell lines and xenografts. Br J Cancer 2003;89:2289-92.
7. van de Wetering M, Barker N, Harkes IC, et al. Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res 2001;61:278-84.
8. Brinkley BR, Beall PT, Wible LJ, Mace ML, Turner DS, Cailleau RM. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res 1980; 40:3118-29.
9. Fujii H, Szumel R, Marsh C, Zhou W, Gabrielson E. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 1996;56:5260-5.
10. Fukino K, Iido A, Teramoto A, et al. Frequent allelic loss at the TOC locus on 17q25.1 in primary breast cancers. Genes Chromosomes Cancer 1999;24: 345-50.
11. Shen CY, Yu JC, Lo YL, et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for imitator phenotype and breast cancer pathogenesis. Cancer Res 2000;60:3884-92.
12. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
13. Gasco M, Yulug IG, Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum Mutat 2003;21:301-6.
14. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92: 564-9.